头颈癌放疗中唾液腺早期萎缩与急性口干症风险增加相关
本研究利用AWARE程序对165例头颈癌患者进行每周锥形束CT监测,发现40.0%患者发生急性口干症。发生口干症者第2、3周腮腺及第2周颌下腺萎缩更显著,且同侧腮腺和颌下腺平均剂量更高;降低腮腺推量照射剂量可降低口干症风险。
要点
- 头颈癌放疗中40.0%患者发生急性口干症。
- 发生口干症者第2、3周腮腺和第2周颌下腺萎缩更明显。
- 同侧腮腺和颌下腺平均剂量较高与口干症风险增加相关。
核心结论
- 同侧腮腺和颌下腺平均剂量增加与放疗期间唾液腺萎缩更显著及急性口干症风险增高相关。
研究设计与样本
- 研究使用AWARE程序每周锥形束CT监测肿瘤和危及器官变化,分析2021至2024年165例可评估的头颈癌患者。
主要发现
- 165例患者中66例(40.0%)发生急性口干症。
- 发生口干症者第2、3周腮腺萎缩分别为15.4%和21.0%,第2周颌下腺萎缩为13.1%,均显著大于无口干症者的11.4%、17.2%和7.7%(t检验P值分别为.047、.032和.007)。
- 发生口干症者同侧腮腺平均剂量为24.7 Gy,显著高于无口干症者的19.8 Gy(P=.003);同侧颌下腺平均剂量为60.7 Gy,显著高于无口干症者的57.4 Gy(P=.045)。
- 锥形束推量照射中较低的腮腺剂量可降低急性口干症风险(P=.015)。
关键数值与推荐
- 急性口干症定义为放疗期间或放疗完成后3个月内发生的≥2级口干症,采用NCI CTCAE v5.0分级。
临床怎么用
- 早期唾液腺萎缩信号可触发及时自适应再计划。
- 锥形束推量和自适应技术可降低唾液腺剂量,有助于减轻急性口干症风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the relationship between geometric and dosimetric characteristics of salivary glands and acute xerostomia during or shortly after radiation therapy in patients with head and neck cancer (HNC). METHODS AND MATERIALS: We used an Automated Watchdog in Adaptive Radiotherapy Environment (AWARE) program to monitor changes in tumor and organ-at-risk using weekly cone beam computed tomography (CT) images for patients with HNC. Gross tumor volume and organ-at-risk contours were propagated from the planning CT to the weekly cone beam CT using deformable registration and reviewed by clinical users. This study analyzed 165 evaluable patients with AWARE-HNC treated between 2021 and 2024. The National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0 was employed to grade toxicities. Acute xerostomia was defined as grade ≥2, occurring during or within 3 months after radiation therapy completion. We compared weekly salivary (parotid and submandibular) gland shrinkage and radiation doses between patients with and without acute xerostomia. RESULTS: Of the 165 patients with HNC, 66 (40.0%) developed acute xerostomia. Patients with acute xerostomia exhibited significantly larger parotid gland shrinkage in the second and third weeks and submandibular gland shrinkage in the second week (15.4%, 21.0%, and 13.1%, respectively; t test P = .047, .032, and .007) during radiation therapy, compared with those without acute xerostomia (11.4%, 17.2%, and 7.7%). Compared with the nonxerostomia group, patients who developed acute xerostomia received significantly higher mean doses to the ipsilateral parotid (24.7 Gy vs 19.8 Gy; P = .003) and ipsilateral submandibular glands (60.7 Gy vs 57.4 Gy; P = .045). Lower parotid dose in the cone-down boost and subsequent adaptation mitigated the risk of acute xerostomia (P = .015). CONCLUSIONS: Increased mean doses to the ipsilateral parotid and submandibular glands were associated with larger salivary gland shrinkage during radiation therapy and a significantly higher risk of acute xerostomia. This early signal could trigger adaptive replanning promptly. Cone-down and adaptive techniques can reduce the salivary gland dose, helping mitigate the risk of acute xerostomia.
引用
- Treechairusame T, Zhang P, Hu YC, et al. Early Salivary Gland Shrinkage Is Associated With an Increased Risk of Acute Xerostomia in Head and Neck Cancer Radiation Therapy. Adv Radiat Oncol. 2026. PMID: 42382855. doi:10.1016/j.adro.2026.102090
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。